SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Khosro Keshavarz, Abbas Kebriaeezadeh, Seyed Moayed Alavian, Ali Akbari Sari, Farid Abedin Dorkoosh, Maryam Keshvari, Seyed Ali Malekhosseini, Saman Nikeghbalian, Shekoufeh Nikfar, Economic Burden of Hepatitis B Virus-Related Diseases: Evidence From Iran, Hepatitis Monthly, 2015, 15, 4

    CrossRef

  2. 2
    Jian-ning Jiang, Zhan-lian Huang, Li-xia He, Yue-hua Huang, Ming-hua Su, Rong Xie, Yan-xiu Liang, Wu-dao Fu, Xiao-hong Huang, Wen-wen Guo, Shao-hua Zhong, Zhi-hong Liu, Shi-hua Li, Tuo-fu Zhu, Zhi-liang Gao, Residual Amount of HBV DNA in Serum is Related to Relapse in Chronic Hepatitis B Patients After Cessation of Nucleos(t)ide Analogs, Journal of Clinical Gastroenterology, 2015, 49, 4, 323

    CrossRef

  3. 3
    J. L. Hou, Z. L. Gao, Q. Xie, J. M. Zhang, J. F. Sheng, J. Cheng, C. W. Chen, Q. Mao, W. Zhao, H. Ren, D. M. Tan, J. Q. Niu, S. J. Chen, C. Pan, H. Tang, H. Wang, Y. M. Mao, J. D. Jia, Q. Ning, M. Xu, S. M. Wu, J. Li, X. X. Zhang, Y. Ji, J. Dong, J. Li, Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial, Journal of Viral Hepatitis, 2015, 22, 2
  4. 4
    Ming-Ling Chang, Yun-Fan Liaw, Hepatitis B flares in chronic hepatitis B: Pathogenesis, natural course, and management, Journal of Hepatology, 2014, 61, 6, 1407

    CrossRef

  5. 5
    En-Qiang Chen, Ying Shi, Dong-Bo Wu, Hong Tang, Liquid oral suspension adefovir dipivoxil (GS-02-526): an update on treatments for hepatitis B infection, Expert Review of Anti-infective Therapy, 2014, 12, 8, 919

    CrossRef

  6. 6
    Stuart Mealing, Isabella Ghement, Neil Hawkins, David A Scott, Benedicte Lescrauwaet, Maureen Watt, Mark Thursz, Pietro Lampertico, Lorenzo Mantovani, Edith Morais, Bruno Bregman, Michel Cucherat, The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis, Systematic Reviews, 2014, 3, 1, 21

    CrossRef

  7. 7
    G.-Q. Wang, Y.-P. Ding, Y.-H. Dong, Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients, Journal of Viral Hepatitis, 2013, 20,
  8. 8
    Steven J. Scaglione, Anna S.F. Lok, Effectiveness of Hepatitis B Treatment in Clinical Practice, Gastroenterology, 2012, 142, 6, 1360

    CrossRef

  9. 9
    Zeng Minde, Mao Yimin, Yao Guangbi, Hou JinLin, Wang Hao, Ren Hong, Wang Yuming, Zhou Xiaqiu, Xu Daozhen, Chen Yagang, Niu Junqi, Chen Youming, Wang Yaozong, Jonathan Dixon, Keith Barker, Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B, Liver International, 2012, 32, 1
  10. 10
    Yu Wang, Jidong Jia, Control of hepatitis B in China: prevention and treatment, Expert Review of Anti-infective Therapy, 2011, 9, 1, 21

    CrossRef

  11. 11
    Mauro Viganò, Pietro Lampertico, Massimo Colombo, Drug safety evaluation of adefovir in HBV infection, Expert Opinion on Drug Safety, 2011, 10, 5, 809

    CrossRef

  12. 12
    Tatyana A. Shamliyan, James R. Johnson, Roderick MacDonald, Aasma Shaukat, Jian-Min Yuan, Robert L. Kane, Timothy J. Wilt, Systematic Review of the Literature on Comparative Effectiveness of Antiviral Treatments for Chronic Hepatitis B Infection, Journal of General Internal Medicine, 2011, 26, 3, 326

    CrossRef

  13. 13
    Vandana Khungar, Steven-Huy Han, A Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B, Current Hepatitis Reports, 2010, 9, 2, 75

    CrossRef

  14. You have free access to this content14
    J.D. Jia, G.B. Yao, Achieving ultimate control of hepatitis B infection in China: progress and challenges, Journal of Viral Hepatitis, 2010, 17,
  15. 15
    Yongwei Li, Mingfen Zhu, Yunwei Guo, Wei Chen, Gang Li, Full-length hepatitis B virus sequences from naïve patients with fluctuation of viral load during ADV monotherapy, Virus Genes, 2010, 40, 2, 155

    CrossRef

  16. 16
    James Fung, Ching-Lung Lai, Man-Fung Yuen, Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B, Expert Review of Anti-infective Therapy, 2010, 8, 6, 717

    CrossRef

  17. 17
    R. G. Gish, T.-T. Chang, C.-L. Lai, R. De Man, A. Gadano, F. Poordad, J. Yang, H. Brett-Smith, R. Tamez, Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B, Journal of Viral Hepatitis, 2010, 17, 1
  18. You have free access to this content18
    J. Sun, J. L. Hou, Management of chronic hepatitis B: experience from China, Journal of Viral Hepatitis, 2010, 17,
  19. 19
    Chanunta Hongthanakorn, Anna S.F. Lok, New Pharmacologic Therapies in Chronic Hepatitis B, Gastroenterology Clinics of North America, 2010, 39, 3, 659

    CrossRef

  20. 20
    Yanfang Jiang, Zhenhua Ma, Guijie Xin, Hongqing Yan, Wanyu Li, Huining Xu, Chunhai Hao, Junqi Niu, Pingwei Zhao, Th1 and Th2 Immune Response in Chronic Hepatitis B Patients during a Long-Term Treatment with Adefovir Dipivoxil, Mediators of Inflammation, 2010, 2010, 1

    CrossRef

  21. 21
    Vito Di Marco, Antonio Craxì, Chronic hepatitis B: who to treat and which choice of treatment?, Expert Review of Anti-infective Therapy, 2009, 7, 3, 281

    CrossRef

  22. 22
    Emilio Palumbo, Clevudine for Chronic Hepatitis B, Infectious Diseases in Clinical Practice, 2009, 17, 4, 217

    CrossRef

  23. 23
    Jinjun Chen, Zhanhui Wang, Yabing Guo, Jie Peng, Jian Sun, Choudhary Shoaib Ahmed, Yuanping Zhou, Jinlin Hou, Serum HBsAg changes in HBeAg positive chronic hepatitis B patients with continuous viral load reductions during treatment with adefovir or peg-interferon-α-2a, Antiviral Research, 2009, 81, 1, 88

    CrossRef

  24. 24
    Mari Inada, Osamu Yokosuka, Current antiviral therapies for chronic hepatitis B, Hepatology Research, 2008, 38, 6
  25. 25
    Jin Hee Cho, Jae Youn Cheong, Joon Koo Kang, Jin Sun Park, Myoung Hee Lee, Nam Kyu Lim, Sun Pyo Hong, Soo-Ok Kim, Wang Don Yoo, Sung Won Cho, Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients, The Korean Journal of Hepatology, 2008, 14, 1, 58

    CrossRef

  26. 26
    Ji-dong Jia, Hepatitis B in China: from guideline to practice, Virologica Sinica, 2008, 23, 2, 152

    CrossRef

  27. 27
    Emilio Palumbo, New Drugs for Chronic Hepatitis B: A Review, American Journal of Therapeutics, 2008, 15, 2, 167

    CrossRef

  28. 28
    Nancy Leung, Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues, Hepatology International, 2008, 2, 2, 163

    CrossRef

  29. 29
    Maureen M. Jonas, Deirdre Kelly, Henry Pollack, Jacek Mizerski, Jeff Sorbel, David Frederick, Elsa Mondou, Franck Rousseau, Etienne Sokal, Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B, Hepatology, 2008, 47, 6
  30. 30
    S. G. LIM, P. MARCELLIN, N. TASSOPOULOS, S. HADZIYANNIS, T. T. CHANG, M. TONG, W. SIEVERT, P. HU, S. ARTERBURN, C. L. BROSGART, Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B, Alimentary Pharmacology & Therapeutics, 2007, 26, 10
  31. 31
    H. L.-Y. CHAN, V. W.-S. WONG, C.-H. TSE, A. M.-L. CHIM, H.-Y. CHAN, G. L.-H. WONG, J. J.-Y. SUNG, Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B, Alimentary Pharmacology & Therapeutics, 2007, 25, 8
  32. 32
    María Buti, Francisco Rodríguez Frías, José Luis Calleja, Rosendo Jardí, Fernando Pons, Javier Crespo, Teresa Casanovas, Jaime Enríquez, Fernando Carnicer, Manuel Romero, Manuel García Bengoechea, Martín Prieto, Javier García Samaniego, Manuel Miras, Francisco Pérez Roldán, Magdalena Rueda, Rafael Esteban, Programa de uso compasivo con adefovir dipivoxil en España: valoración de su eficacia y estudio de las resistencias, Medicina Clínica, 2007, 129, 15, 566

    CrossRef

  33. 33
    Victor Pérez, Viral Hepatitis: Historical Perspectives from the 20th to the 21st Century, Archives of Medical Research, 2007, 38, 6, 593

    CrossRef

  34. 34
    Erik De Clercq, 2007,

    CrossRef

  35. 35
    Oliver Schildgen, Martin Helm, Wolfram Gerlich, Nonresponse to adefovir: Host or virus dependent?, Journal of Clinical Virology, 2006, 37, 4, 327

    CrossRef

  36. 36
    Piero Luigi Almasio, Calogero Cammà, Vito Di Marco, Antonio Craxì, Hepatitis B: Prognosis and Treatment,